Navigation Links
XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation

XenaCare Holdings has announced that it has become a national sponsor of the Arthritis Foundation, one of the largest nonprofit organizations dedicated to arthritis research and public health education.

Delray Beach, FL (Vocus) November 27, 2009 -- XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.

With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website,

The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:

  • Advocacy - Local, state and national efforts to advance vital legislation.
  • Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
  • Public health - Information and empowering programs and services.
  • Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.

In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States.

In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.

Benefits to Cobroxin include:

  • All Natural
  • Non-Addictive
  • Non-Narcotic
  • Non-Opiate
  • More Potent than Morphine
  • Long Lasting
The Company’s additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.

Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans to introduce Cobroxin into the commercial marketplace and for additional marketing campaigns are forward looking statements. Although these forward looking statements constitute our current plans, the timing, marketing channels and advertising support for the product may change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. American Diversified Holdings Corporation Announces New Website
2. Zimmer Holdings, Inc. Announces Offering of Senior Notes
3. Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009
4. Celsius Holdings, Inc. Invites You to Join its Third Quarter 2009 Financial Results Conference Call on Tuesday, November 10, 2009, at 4:30 p.m. Eastern
5. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
6. CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change
7. JAG Media Holdings, Inc. Amends Articles of Incorporation
8. Select Medical Holdings Corporation Successfully Completes Initial Public Offering of Common Stock
9. CMHS (dba Hybrid Energy Holdings) changes name of corporation and prepares to file for ticker symbol change with FINRA
10. Pacific Shore Holdings, Inc. Begins Clinical Trial With Burner Balm
11. JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.
Post Your Comments:
Related Image:
XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: